New trial shows top-selling Lundbeck drug not beating placebo for borderline

A phase II trial of one of Lundbeck's best-selling drugs for borderline personality disorder has not shown the hoped-for result, as the drug doesn't outperform the placebo treatment in the study's focal point.
Photo: Lundbeck / PR
Photo: Lundbeck / PR

Lundbeck suffers a setback in its attempts to promote the use of Rexulti, which is already among the company's best-selling products, reads the pharmaceutical company's Q2 report released Wednesday morning.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading